EGFR exon 20 insertion (EGFRex20ins) mutations are uncommon mutations in non-small cell lung cancer (NSCLC) that are associated with resistance to TKI therapy. Although two new targeted therapies have ...
Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling. Shared insight on how molecular profiling can ...
Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...
An oral EGFR/HER2 inhibitor led to high levels of disease control in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, data from two ongoing phase I ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
Credit: FDA. According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required. The Food and Drug ...
The top content from the World Conference on Lung Cancer (WCLC) 2025 highlighted panels and abstracts presented during the event, including updated MARIPOSA data, emerging data in EGFR -positive ...
Takeda Pharmaceutical’s cancer drug portfolio has added another FDA approved product, a targeted therapy that addresses tumors carrying a rare genetic signature. The FDA approved the Takeda drug, ...
KIT-exon-11 mutations in GISTs correlate with higher partial response rates and improved surgical outcomes with neoadjuvant Gleevec. Non-KIT exon 11 mutations and wild-type KIT/PDGFRA GISTs show less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback